Psychosis in the Young
Prof Chris Hollis
Developmental Psychiatry Section
Division of Psychiatry
University of Nottingham
Outline
Child & Adolescent Onset Schizophrenia (CAOS)
History & Concepts Clinical Features Epidemiology Differential Diagnosis Course and Outcome Developmental Features Neurobiology Pharmacological Treatment
History of Psychosis & Schizophrenia in the Young Child & adolescent presentations
recognised by Kraepelin and Bleuler Mid 20th century – Broad ‘Childhood
Schizophrenia’ concept includes autism and other developmental disorders
1970s: Rutter & Kolvin ->separation of autism from schizophrenia in childhood
DSM-III same diagnostic criteria used for schizophrenia in children and adults
New Approaches to Schizophrenia Neurodevelopment Dimensional view Genes for ‘risk’ not disorder Focus on ‘intermediate’ neurocognitive
processes or endophenotypes Partial dopamine agonists (Aripiprazole) Renewed interest in social &
environmental causes and moderation of gene expression
Prenatal Childhood Adolescence Adult
Psychosis
Genes Environment
Subtle developmental & social impairments
Negative/ schizotypal/ prodromal symptoms
Early intervention
?
From Risk to Disorder
Drugs ? Stress ?
Clinical Features of CAOS
Phases of Illness
1. Pre-Psychotic2. Prodromal/ Peri-Psychotic3. Psychosis4. Post-Psychotic
1. Pre-Psychotic Phase Developmental impairments
Language Motor Social Attention/ cognition (executive
function) Disruption of fronto-striatal circuits
(reduced fronto-cortical DA activity?) Non-specific – not useful predictors
Premorbid Developmental Problems
Schizophrenia Other Psychoses Statistics
N=61 N=48
% (N) % (N) P value
Language delay 19 (11) 9 (4) 0.2
Reading delay 28 (17) 22 (10) 0.6
Motor delay 7 (4) 9 (4) 0.7
Primary enuresis 36 (20) 18 (8) 0.06
Social impairment: possible 20 (12) 9 (4)
definite 14 (8) 4 (2) <0.04
Definite OCs 16 (9) 18 (7) 0.4
Hollis C (2003) British Journal of Psychiatry, 182, 37-44
Premorbid adjustment in adolescent psychoses
0
2
4
6
8
10
Schizophrenia
Other PsychosesMedian
PAS score
P<0.0002
Impairment
2. Prodromal Phase
Progressive social and cognitive decline
Incongruous, bizarre behaviour Subtle perceptual & affective
changes Early negative symptoms Disorganisation
Age of Onset of Prodromal and Psychotic Symptoms
0
5
10
15
20
25
30
35
6 7 8 9 10 11 12 13 14 15 16 17
Behaviouralchange
Psychosis
Age
Frequency
3. Psychotic (Active) Phase
Positive symptoms (may be hard to elicit) – non specific for schizophrenia
Affective symptoms are common Dopamine dysregulation
Increased mesocortical DA activity Cannabis, DA agonists Psychosocial stressors
4. Post Psychotic Phase Probability of remission
predicted by: Premorbid functioning Duration of active phase
symptoms
50% maintain chronic course
Remission From First Psychotic Episode
0%
20%
40%
60%
80%
100%
None
Incomplete
Complete
Schizophrenia Affective psychosis X2=23; P<0.0001
12%
40%
48%
52%
38%
10%
Hollis C (2000) Am J Psychiatry; 157; 1652-1659
Clinical Features - Summary
Premorbid impairments – resemble other neurodevelopmental disorders e.g. ASD/ ADHD
Insidious onset, cognitive & social decline Negative symptoms, disorganisation Hallucinations, delusions can be difficult to
elicit Affective symptoms common Diagnostic uncertainty High rates of non-remission
Epidemiology
Trent EPIC Study
Hollis et al. (2004) Incidence of adolescent-onset psychosis in the Trent Region of the U.K. Schizophrenia Research, 67 (Suppl), 65
Numerator: All incident cases of psychosis (ICD-10 F20.1-29.0 & F30.0-39.0), onset <=16 years in Trent region in 48 month period
Denominator: Total population at risk age 6-16
EPIC Study
0
5
10
15
20
25
10 11 12 13 14 15 16
Age of Onset of Psychosis
Age
Number of Cases
Age Specific Incidence Rates
Age Number of cases Incidence rate per 100,000 person years
10
11
12
13
14
15
16
10-16
1
5
5
4
16
14
22
67
0.39
1.93
1.93
1.55
6.19
5.42
8.51
3.7 (95% CI 2.9-4.7)
1.4
6.7
Hollis et al. (2004). Schizophrenia Research, 67 (Suppl), 65
Incidence rate Ratios for Psychosis (Age 10-16)
Risk Variable
Incidence Rate Ratio (95% CI)
Significance
Social Class (SES) low vs. high 2.8 (1.3 - 5.9)
Gender male vs. female
Ethnicity non-white vs. white
African Caribbean vs. whiteAge 14-16 vs. 10-13
1.0 (0.6 – 1.6)
2.1 (0.9 – 5.4)
10.1 (3.2 – 31.0)
4.6 (2.7 – 7.8)
P<0.005
P=0.5 (ns)
P=0.02
P<0.001
P<0.001
Hollis et al. (2004). Schizophrenia Research, 67 (Supply), 65
Differential Diagnosis Affective Psychosis (BAD, MDD, SAD) ASD – Asperger’s MDI/ Schizotypal PD Dissociative disorder, Borderline PD, PTSD Drugs Epilepsy (TLE, frontal seizures) Neuropsychiatric
Auto-immune, SLE Degenerative: Wilson’s, MLD, ALD,
Huntingdon’s
Course & Outcome
High diagnostic stability (80%) for DSM-IV schizophrenia in adolescence
High levels of chronic social and symptomatic impairment
Predictors of poor outcome Premorbid impairment Negative symptoms
Hollis C (2000) Am J Psychiatry; 157; 1652-1659
Follow-up Time Psychotic
0 2 4 6 8 10 12
Affectivepsychosis
Schizophrenia
Psychotic
Remission
66%
years
30%
Hollis C (2000) Am J Psychiatry; 157; 1652-1659
Accommodation at Follow-Up
0%
20%
40%
60%
80%
100%
long stay
hostel/ home
independent
Schizophrenia Affective psychosis
16%
39%
45%
52%
21%
26%
X2=15; P=0.01
Hollis C (2000) Am J Psychiatry; 157; 1652-1659
Relationships at Follow-Up
0%
20%
40%
60%
80%
100%
Partner
Friends
Aquaintence
None
Schizophrenia Affective psychosis
44%
40%
14%
14%
29%
31%
26%
X2=21; P<0.001
Hollis C (2000) Am J Psychiatry; 157; 1652-1659
Predictors of Poor Outcome
Baseline Predictors* B p value
‘Negative Symptoms’ 0.58 <0.000
‘Developmental’ factor 0.24 0.002
‘Disorganisation’ 0.14 0.045
‘Depression’ factor -0.18 0.007
‘Mania’ factor -0.17 0.016
Non-significant predictors: positive symptom factor 1 & 2; diagnosis; family discord; perinatal complications; gender; duration of illness
* Model R2 = 0.72; stepwise variable entry
Neurobiology Reduced total cortical grey matter
volume (20%) Increased ventricular volume (40%) Temporal lobe reductions less marked
than in adults Progressive loss of grey matter volume
follows “back to front” cortical wave Volume loss plateaus in late adolescence Rate of volume reduction correlates with
poor pre-morbid function
Sporn et al. (2003) Am J Psychiatry; 160, 2181-2189
Developmental Brain Changes
50
10
15 20 25 30 35
Age
Synaptic density
5
10
15
20
(mm-3x108)
PSSP
PS = proliferative stage
SP = synaptic pruning
Developmental Brain Changes
50
10
15 20 25 30 35
Age
Synaptic density
5
10
15
20
(mm-3x108)
PSSP
PS = proliferative stage
SP = synaptic pruning
Childhood-onset Schizophrenia
Developmental Brain Changes
50
10
15 20 25 30 35
Age
Synaptic density
5
10
15
20
(mm-3x108)
PSSP
PS = proliferative stage
SP = synaptic pruning
Childhood-onset Schizophrenia
Progressive Brain Changes
Sporn et al. (2003) Am J Psychiatry; 160, 2181-2189
Age of Onset and Familial Risk
DSM-IIIR Schizophrenia Probands
FH-RDC Positive Adolescent-onset† Adult-onset‡ Statistics
status of proband N=61 N=101
% (n) % (n) z-test P value
Schizophrenia 20 (12) 13 (13) 0.86 0.39
Any Psychosis 46 (28) 23 (25) 3.18 <0.002
† Maudsley Follow-up study (Hollis, C (2000) Am J Psychiatry, 157; 1652-1659.
‡ Camberwell Collaborative Psychosis Study (Sham et al., 1994)
SONAR: Adolescents At-Risk of Schizophrenia
Schizophrenia
Age 14-20 N=30
Siblings of Schizophrenia
Probands
Age 14-20 N=30
ADHD
Age 14-20 N=30
Healthy Controls
Age 14-20 N=30
Cognitive Assessment:
Verbal learning, Hayling sentence completion, WAISI, visual backward masking, spatial working memory, CPT (DS)
Measures of Brain Activity:
ERP: P50, MMN, auditory odd-ball, Go-NoGo
fMRI: Auditory odd-ball, Go-NoGo
[Hollis, Liddle, Jackson et al.]
SONAR: Adolescents At-Risk of Schizophrenia
Schizophrenia
Age 14-20 N=30
Siblings of Schizophrenia
Probands
Age 14-20 N=30
ADHD
Age 14-20 N=30
Healthy Controls
Age 14-20 N=30
Cognitive Assessment:
Verbal learning, Hayling sentence completion, WAISI, visual backward masking, spatial working memory, CPT (DS)
Measures of Brain Activity:
ERP: P50, MMN, auditory odd-ball, Go-NoGo
fMRI: Auditory odd-ball, Go-NoGo
[Hollis, Liddle, Jackson et al.]
EEG
ERP tasks
Auditory Odd-Ball Stimuli: sine wave tones
delivered through headphones
Standard: 1000Hz – 85% Target: 1500Hz – 15% Instruction to press a
response button on presentation of each target tone
-50
-25
0
25
50
µv
ms
200 300100 400 5000
P300S R
P300: P300: •stimulus evaluationstimulus evaluation•Up-dating internal context and Up-dating internal context and memory models in situations memory models in situations requiring stimulus categorisationrequiring stimulus categorisation
30
25
20
15
10
5
0
-5
-10
-15
-20
-25
-30
[µV]
-200 -100 0 100 200 300 400 500 600 700 800 [ms]
P300 to target tones at Pz
HealthyADHD
SZSZ High Risk
Specificity?
Groups standardised to healthy group mean
-2
-1.8
-1.6
-1.4
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
P300 N200 FI N200 SI ERN Error PosHealthy
ADHDSZSZ HR
Are Adolescents Different?
Phenomenology same
Stability of diagnosis same
Predictive validity of schizophrenia same
Outcome of psychoses worse
Premorbid/ developmental functioning worse
Familial psychiatric risk worse
Treatment
Pharmacotherapy is cornerstone Reduce environmental stress Psychoeducation: patient, family, school Psychotherapy: CBT, family therapy Education/ training Social support – voluntary groups N.B. NICE Clinical Guidance on
Schizophrenia (December 2002) doesn’t cover < age 18
Response to Traditional Antipsychotics
Treatment resistance common Poor response of negative symptoms Side effects common: sedation,
dystonias, EPSE, WD -> reduced compliance
Long life-time exposure increases risk of TD
Enlargement of caudate nucleus (Frazier et al 1996) reversed by clozapine.
Atypical Antipsychotics
Risperidone, Olanazepine, Quetiapine, Clozapine, Amisulpiride, (Zotepine)…. Now standard antipsychotic choice for children & adolescents (70-80%) Very limited evidence-base in younger patients (1 RCT) Possible increased efficacy against negative symptoms, cognitive impairment Variable profile of side effects, reduced EPSE
Side-Effects of AntipsychoticsCan be more severe in children/ adolescents than adults and include:
Dystonias/ EPSE/ TD Increased appetite and weight gain Type II diabetes & lipid changes Blood dyscrasias (neutropenia/ agranulocytosis) Cardiac arrhythmias, QTc interval Elevated prolactin -> estrogen, osteoperosis Seizures
Incidence of EPSE by Age
0
10
20
30
40
50
60
70
10 to 19 20 to 29 30 to 39 40 to 49 50 to 59
DystoniaParkinsonismAkathisia
Inci
den
ce
%
Age [Adapted from Remschmidt 2000]
Weight Gain in Adolescents Olanzepine vs. Risperidone vs. Haloperidol
0
2
4
6
8
10
12
0 1 2 3 4 5 6 7 8 9 10 11 12
OlanzapineRisperidoneHaloperidol
Mean %
Weig
ht
Chan
ge
Week[Ratzoni et al. (2002) JAACAP, 41, 337-343]
N=21
N=21
N=8
*
*
* p<0.01 wk12 vs. baseline
Mean age 17 yrs
Mean dosage:
Olanzapine 12.7mg
Risperidone 3.2mg
Haloperidol 7.6mg
Weight Gain on Atypicals: Adolescents vs. Adults
0
1
2
3
4
5
6
7
8
Olanzapine Risperidone Haloperidol
AdolescentsAdults
Mean
Wt
Gain
Kg
*
**
* Ratzioni et al (2002) JAACAP, 41: 337-341
** Allison et al (1999) Am J Psych, 60: 215-220
Treatment - Summary Schizophrenia in children and adolescents
requires early, aggressive, treatment Atypicals are first-line treatment All atypicals have side-effects Side effect profiles differ between drugs – may
influence choice e.g. quetiapine in adolescent girls
Children and adolescents may be more sensitive to side effects e.g. EPSE, weight gain, seizures
Urgent need for more empirical data on effectiveness and side-effect profiles of longer term treatment
References Hollis C (2003) developmental precursors of child- and adolescent-onset
schizophrenia and affective psychoses: diagnostic specificity and continuity with symptom dimensions. British Journal of Psychiatry, 182, 37-44.
Hollis, CP & Taylor E (1997) Schizophrenia: a critique from the developmental psychopathology perspective. In: (Eds: Murray, R & Keshavan MS) Neurodevelopment and Adult Psychopathology, Cambridge: Cambridge University Press, 1987
Hollis CP (2000) Adolescent schizophrenia. Advances in Psychiatric Treatment. 6, 83-92
Hollis CP (2000) The adult outcomes of child and adolescent-onset schizophrenia: Diagnostic stability and predictive validity. American Journal of Psychiatry, 157; 1653-1659.
Cannon M, Walsh E, Hollis C et al. (2001) Predictors of later schizophrenia and affective psychosis among attendees at a child psychiatry department. British Journal of Psychiatry, 178: 420-426.
Hollis C (2001) Diagnosis and differential diagnosis. In: Schizophrenia in Children and Adolescents, Ed. H. Remschmidt. Cambridge: Cambridge University Press.
Hollis C (2002) Schizophrenia and allied disorders. In, Child and Adolescent Psychiatry (4th Edition). Eds. M Rutter and E Taylor. Blackwell: Oxford.
Hollis C (2003) Child and adolescent-onset schizophrenia. In, Schizophrenia (2nd Edtion). Ed SR Hirsch & DL Weinberger). Blackwell: Oxford.